|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.260 USD | -6.67% |
|
+2.44% | -30.77% |
| 07-22 | Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026 | CI |
| 07-21 | Alzamend Neuro, Inc. Announces Demise of Lynne Fahey Mcgrath, Director on July 20, 2026 | CI |
Evolution of the Average Target: Alzamend Neuro, Inc.
Evolution of the Target Price: Alzamend Neuro, Inc.
Changes in Analyst Recommendations: Alzamend Neuro, Inc.
fb1ac1014ffaf7a.bjhkLZNdt6fLl-ADbc5DcjkZUSDZDRyFNLShOjyjX5o.WFQNb90YzuS846JkKaI5FnorZGyze2WwYpniaHrxGfYKdiMe4QL43rvVpQ~3871173b4125b27110f7188e7276e1ea
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | - | - | +1,751.85% | |||
| +24.99% | |||||
| +11.38% | |||||
| +29.66% | |||||
| +16.86% | |||||
| +50.89% | |||||
| +20.22% | |||||
| -10.56% | |||||
| +1.85% | |||||
| +8.69% | |||||
| Average | +190.58% | |||||
| Weighted average by Cap. | +20.42% |
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.260USD
Average target price
25.00USD
Spread / Average Target
+1,884.13%
High Price Target
25.00USD
Spread / Highest target
+1,884.13%
Low Price Target
25.00USD
Spread / Lowest Target
+1,884.13%
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Maxim | |
| Ascendiant Capital |
SellBuy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.260USD
Average target price
25.00USD
Spread / Average Target
+1,884.13%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALZN Stock
- Consensus Alzamend Neuro, Inc.
Select your edition
All financial news and data tailored to specific country editions
